Ji-Yan Liu Selected Research

raltitrexed (D 1694)

1/2022	Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study.
1/2022	Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial.
1/2021	Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
1/2019	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
10/2013	Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ji-Yan Liu Research Topics

Disease

38	Neoplasms (Cancer) 07/2022 - 02/2002
15	Colorectal Neoplasms (Colorectal Cancer) 07/2022 - 07/2011
5	Neoplasm Metastasis (Metastasis) 07/2021 - 09/2008
4	Stomach Neoplasms (Stomach Cancer) 09/2020 - 05/2016
4	Hepatocellular Carcinoma (Hepatoma) 04/2013 - 03/2006
3	Penile Neoplasms (Penile Cancer) 03/2022 - 09/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2021 - 11/2011
3	Type 2 Diabetes Mellitus (MODY) 10/2016 - 11/2011
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2016 - 01/2013
3	Carcinoma (Carcinomatosis) 01/2016 - 01/2005
3	Pulmonary Tuberculosis 01/2015 - 01/2014
2	Disease Progression 01/2021 - 01/2016
2	Colonic Neoplasms (Colon Cancer) 01/2020 - 12/2010
2	Infections 01/2018 - 02/2014
2	Lung Neoplasms (Lung Cancer) 09/2017 - 06/2005
2	Lung Diseases (Lung Disease) 01/2015 - 10/2011
2	Anemia 01/2012 - 01/2011
1	Pneumonia (Pneumonitis) 01/2022
1	Inflammation (Inflammations) 11/2021
1	COVID-19 01/2021
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2021
1	Cardiotoxicity 01/2019
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2018
1	Extramammary Paget Disease (Paget Disease, Extramammary) 01/2018
1	Carcinogenesis 01/2018
1	Lymphatic Metastasis 10/2016
1	Adenocarcinoma 05/2016
1	Peritoneal Neoplasms 05/2016
1	Ascites 05/2016
1	Malignant Mesothelioma 01/2016
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 04/2015
1	Hepatitis 04/2015

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 07/2021 - 09/2003
10	VaccinesIBA 04/2011 - 02/2002
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2005
5	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 12/2010
5	raltitrexed (D 1694)IBA 01/2022 - 10/2013
5	Immunoglobulins (Immunoglobulin)IBA 03/2006 - 02/2002
4	Bevacizumab (Avastin)FDA Link 07/2022 - 10/2013
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
4	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2013
4	Biological ProductsIBA 01/2021 - 01/2005
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 10/2011
4	Gemcitabine FDA Link 01/2016 - 01/2005
3	LigandsIBA 01/2022 - 02/2002
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 10/2013
3	Calcibiotic Root Canal SealerIBA 07/2021 - 01/2013
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
3	Cetuximab (Erbitux)FDA Link 01/2021 - 10/2015
3	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 09/2013
3	Sunitinib (Sutent)FDA Link 09/2017 - 06/2011
3	AntigensIBA 01/2013 - 02/2002
3	AutoantibodiesIBA 03/2006 - 02/2002
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 04/2005 - 09/2003
2	CTLA-4 AntigenIBA 01/2022 - 01/2019
2	Cadherins (E-Cadherin)IBA 07/2021 - 09/2017
2	CateninsIBA 07/2021 - 09/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 01/2016
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 06/2011
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 04/2005
2	Thymidylate SynthaseIBA 01/2019 - 09/2013
2	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2019 - 09/2013
2	apatinibIBA 01/2018 - 01/2018
2	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 11/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2017 - 03/2006
2	Blood Proteins (Serum Proteins)IBA 01/2015 - 10/2011
2	Growth Factor ReceptorsIBA 01/2014 - 09/2003
2	Hemoglobins (Hemoglobin)IBA 01/2012 - 01/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2010 - 09/2005
2	AlginatesIBA 09/2008 - 09/2003
2	Combined VaccinesIBA 09/2005 - 04/2005
1	tislelizumabIBA 03/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	regorafenibIBA 01/2022
1	AS 35IBA 09/2020
1	Lapatinib (GW572016)FDA Link 01/2020
1	human ERBB2 proteinIBA 01/2020
1	pyrotinibIBA 01/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	Cancer VaccinesIBA 01/2019
1	Cyclin D1IBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2018
1	VimentinIBA 09/2017
1	Insulin-Like Growth Factor I (IGF-1)IBA 10/2016
1	PolyphenolsIBA 07/2016
1	TeaIBA 07/2016
1	Tumor Biomarkers (Tumor Markers)IBA 01/2016
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 04/2015
1	Antiviral Agents (Antivirals)IBA 04/2015
1	Superoxide Dismutase-1IBA 01/2015
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2015

Therapy/Procedure

26	Drug Therapy (Chemotherapy) 07/2022 - 01/2005
19	Therapeutics 01/2022 - 02/2002
5	Radiotherapy 01/2022 - 01/2008
5	Immunotherapy 03/2006 - 09/2003
1	Combination Drug Therapy (Combination Chemotherapy) 03/2022
1	Chemoradiotherapy 01/2020
1	Cytoreduction Surgical Procedures 01/2016
1	Hyperthermic Intraperitoneal Chemotherapy 01/2016
1	Neoadjuvant Therapy 10/2015